Drugs / ILB2109
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05278546 | Apr 2022 → Dec 2024 overdue | neoplasm | Innolake Biopharm | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05955105 | Jul 2023 → Jan 2026 overdue | cervical cancer, classic Hodgkin lymphoma, endometrial cancer, melanoma +5 | Innolake Biopharm | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILB-2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05955105 ↗ |
| Route | Oral | “ILB2109 tablets by mouth once per day” NCT05278546 ↗ |